This indicates that SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade could enhance the clearance of AML-initiating cells, which may be used as promising therapeutic interventions for AML [90]. This evidence concerns the gene SIRPA and acute myeloid leukemia.